Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?
Current Treatment Options in Oncology · 2024-04 · 25 (4) · 405-426
DOI: 10.1007/s11864-024-01186-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 17.02.2024. Verfasst von Sietske C M W van Nassau und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, PO Box 85500, Utrecht, 3584 CX, The Nether…. Hauptthemen laut MEDLINE: Colorectal Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Opinion statement Treatment guidelines for colorectal cancer (CRC) are primarily based on the results of randomized clinical trials (RCTs), the gold standard methodology to evaluate safety and efficacy of oncological treatments. However, generalizability of trial results is often limited due to stringent eligibility criteria, underrepresentation of specific populations, and more heterogeneity in clinical practice. This may result in an efficacy-effectiveness gap and uncertainty regarding meaningful benefit versus treatment harm. Meanwhile, conduct of traditional RCTs has become increasingly challenging due to identification of a growing number of (small) molecular subtypes. These challenges—combined with the digitalization of health records—have led to growing interest in use of real-world data (RWD) to complement evidence from RCTs. RWD is used to evaluate epidemiological trends, quality of care, treatment effectiveness, long-term (rare) safety, and quality of life (QoL) measures. In addition, RWD is increasingly considered in decision-making by clinicians, regulators, and payers. In this narrative review, we elaborate on these applications in CRC, and provide illustrative examples. As long as the quality of RWD is safeguarded, ongoing developments, such as common data models, federated learning, and predictive modelling, will further unfold its potential. First, whenever possible, we recommend conducting pragmatic trials, such as registry-based RCTs, to optimize generalizability and answer clinical questions that are not addressed in registrational trials. Second, we argue that marketing approval should be conditional for patients who would have been ineligible for the registrational trial, awaiting planned (non) randomized evaluation of outcomes in the real world. Third, high-quality effectiveness results should be incorporated in treatment guidelines to aid in patient counseling. We believe that a coordinated effort from all stakeholders is essential to improve the quality of RWD, create a learning healthcare system with optimal use of trials and real-world evidence (RWE), and ultimately ensure personalized care for every CRC patient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, PO Box 85500, Utrecht, 3584 CX, The Netherlands. s.c.m.vannassau@umcutrecht.nl.
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, PO Box 85500, Utrecht, 3584 CX, The Netherlands.
- Department of Epidemiology & Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
- Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Zitieren
APA
van Nassau, S. C. M. W., Bol, G. M., van der Baan, F. H., Roodhart, J. M. L., Vink, G. R., Punt, C. J. A., May, A. M., Koopman, M., & Derksen, J. W. G. (2024). Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?. Current Treatment Options in Oncology, 25(4), 405-426. https://doi.org/10.1007/s11864-024-01186-4
Vancouver
van Nassau SCMW, Bol GM, van der Baan FH, Roodhart JML, Vink GR, Punt CJA, et al. Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?. Current Treatment Options in Oncology. 2024;25(4):405-426. doi:10.1007/s11864-024-01186-4
BibTeX
@article{vanNassau2024,
author = {van Nassau, Sietske C M W and Bol, Guus M and van der Baan, Frederieke H and Roodhart, Jeanine M L and Vink, Geraldine R and Punt, Cornelis J A and May, Anne M and Koopman, Miriam and Derksen, Jeroen W G},
title = {Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?},
journal = {Current Treatment Options in Oncology},
year = {2024},
volume = {25},
number = {4},
pages = {405--426},
doi = {10.1007/s11864-024-01186-4}
}
EUVIMED